A detailed history of Advisor Group Holdings, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 12,039 shares of SMMT stock, worth $228,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,039
Previous 450 2575.33%
Holding current value
$228,500
Previous $3,000 8666.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.89 - $31.93 $79,848 - $370,036
11,589 Added 2575.33%
12,039 $263,000
Q2 2024

Aug 13, 2024

SELL
$2.39 - $10.92 $27,272 - $124,608
-11,411 Reduced 96.21%
450 $3,000
Q1 2024

May 10, 2024

SELL
$2.55 - $5.07 $336,842 - $669,721
-132,095 Reduced 91.76%
11,861 $49,000
Q4 2023

Feb 12, 2024

SELL
$1.67 - $2.83 $42,788 - $72,510
-25,622 Reduced 15.11%
143,956 $375,000
Q3 2023

Nov 13, 2023

BUY
$1.54 - $2.42 $1,848 - $2,904
1,200 Added 0.71%
169,578 $317,000
Q2 2023

Aug 10, 2023

BUY
$1.32 - $2.81 $16,907 - $35,993
12,809 Added 8.23%
168,378 $422,000
Q1 2023

May 12, 2023

BUY
$1.38 - $5.41 $150,965 - $591,826
109,395 Added 236.92%
155,569 $272,000
Q4 2022

Feb 10, 2023

BUY
$0.68 - $5.31 $3,944 - $30,797
5,800 Added 14.37%
46,174 $196,000
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.63 $26,498 - $48,531
29,774 Added 280.89%
40,374 $48,000
Q2 2022

Aug 10, 2022

BUY
$0.92 - $2.38 $920 - $2,380
1,000 Added 10.42%
10,600 $11,000
Q1 2022

May 04, 2022

SELL
$2.0 - $3.45 $2,960 - $5,106
-1,480 Reduced 13.36%
9,600 $24,000
Q3 2021

Nov 05, 2021

BUY
$4.83 - $8.27 $24,633 - $42,177
5,100 Added 85.28%
11,080 $56,000
Q2 2021

Aug 02, 2021

BUY
$5.15 - $8.46 $30,797 - $50,590
5,980 New
5,980 $44,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.82B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.